AKT1 and acute myeloid leukemia: HHT in combination with heat shock protein 90 (HSP90) inhibitors synergistically reduces FLT3 expression and inhibits downstream signaling pathways, including STAT5, AKT, ERK, and 4E-BP1, demonstrating efficacy in treating FLT3-ITD-positive acute myeloid leukemia (AML) (198).